Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020

Д. С. Лебедев; Е. Н. Михайлов; Н. М. Неминущий; Е. З. Голухова; В. Е. Бабокин; В. В. Березницкая; Е. С. Васичкина; С. В. Гарькина; С. П. Голицын; К. В. Давтян; Д. В. Дупляков; Е. В. Заклязьминская; С. А. Зенин; Э. А. Иваницкий; Р. А. Ильдарова; В. Н. Комолятова; А. А. Костарева; Е. А. Кучинская; Л. Ю. Лайович (Нестеренко); В. К. Лебедева; Т. А. Любимцева; Л. М. Макаров; С. Е. Мамчур; М. М. Медведев; Н. Ю. Миронов; Л. Б. Митрофанова; С. В. Попов; А. Ш. Ревишвили; Ф. Г. Рзаев; А. Б. Романов; Р. Б. Татарский; С. А. Термосесов; М. Д. Уцумуева; М. С. Харлап; Д. А. Царегородцев; М. А. Школьникова; Н. Б. Шлевков; Е. В. Шляхто; Ю. В. Шубик; С. М. Яшин

Статья

Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020

Д. С. Лебедев, Е. Н. Михайлов, Н. М. Неминущий, Е. З. Голухова, В. Е. Бабокин, В. В. Березницкая, Е. С. Васичкина, С. В. Гарькина, С. П. Голицын, К. В. Давтян, Д. В. Дупляков, Е. В. Заклязьминская, С. А. Зенин, Э. А. Иваницкий, Р. А. Ильдарова, В. Н. Комолятова, А. А. Костарева, Е. А. Кучинская, Л. Ю. Лайович (Нестеренко), В. К. Лебедева, Т. А. Любимцева, Л. М. Макаров, С. Е. Мамчур, М. М. Медведев, Н. Ю. Миронов, Л. Б. Митрофанова, С. В. Попов, А. Ш. Ревишвили, Ф. Г. Рзаев, А. Б. Романов, Р. Б. Татарский, С. А. Термосесов, М. Д. Уцумуева, М. С. Харлап, Д. А. Царегородцев, М. А. Школьникова, Н. Б. Шлевков, Е. В. Шляхто, Ю. В. Шубик, С. М. Яшин

2021

https://doi.org/10.15829/1560-4071-2021-4600

Российское кардиологическое общество (РКО).При участии: Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА); Всероссийской общественной организации “Ассоциация детских кардиологов России”; Общества холтеровского мониторирования и неинвазивной электрокардиологии.Одобрено Научно-практическим Советом Минздрава Российской Федерации.

Лебедев Д. С., Михайлов Е. Н., Неминущий Н. М., Голухова Е. З., Бабокин В. Е., Березницкая В. В., Васичкина Е. С., Гарькина С. В., Голицын С. П., Давтян К. В., Дупляков Д. В., Заклязьминская Е. В., Зенин С. А., Иваницкий Э. А., Ильдарова Р. А., Комолятова В. Н., Костарева А. А., Кучинская Е. А., Лайович (Нестеренко) Л. Ю., Лебедева В. К., Любимцева Т. А., Макаров Л. М., Мамчур С. Е., Медведев М. М., Миронов Н. Ю., Митрофанова Л. Б., Попов С. В., Ревишвили А. Ш., Рзаев Ф. Г., Романов А. Б., Татарский Р. Б., Термосесов С. А., Уцумуева М. Д., Харлап М. С., Царегородцев Д. А., Школьникова М. А., Шлевков Н. Б., Шляхто Е. В., Шубик Ю. В., Яшин С. М. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4600. https://doi.org/10.15829/1560-4071-2021-4600

Цитирование

Список литературы

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-2.

2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) “Об основах охраны здоровья граждан в Российской Федерации”.

3. Эпидемиологический словарь. Под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. 4-е изд. Москва, 2009. 316 с.

4. Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТ Р 52379-2005. Надлежащая клиническая практика. Москва, 2005.

5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) “Об обращении лекарственных средств”.

6. Малая медицинская энциклопедия. М.: Медицинская энциклопедия. 1991-96 гг. Режим доступа: http://dic.academic.ru/dic.nsf/enc_medicine/28878/CuHgpoM.

7. Андреева Н. С., Реброва О.Ю., Зорин Н.А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;4:10-24.

8. Eckart RE, Shry EA, Burke AP, et al. Department of Defense Cardiovascular Death Registry G. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J. Am. Coil. Cardiol. 2011;(58):1254-61.

9. van der Werf C, Hendrix A, Birnie E, et al. Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community-based intervention study. Europace. 2016;18(4):592-601. doi:10.1093/europace/euv059.

10. United Nations Economic Commission for Europe. UNECE statistical database. Available at http://w3.unece.org/pxweb.

11. Макаров Л.М., Комолятова В.Н., Киселева И.И., Солохин Ю.А. Распространенность внезапной сердечной смерти у лиц молодого возраста в крупном мегаполисе. Медицинский алфавит. 2014;3(Кардиология № 1):35-40.

12. Бокерия Л. А., Ревишвили А. Ш., Неминущий Н. М. Внезапная сердечная смерть. М.:ГЭОТАР-Медиа. 2011. 267 с.

13. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85:I2-10.

14. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012;33:1635-701.

15. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99:1978-83.

16. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;77:155-60.

17. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation. 2006;114:1462-7.

18. Bezzina CR, Pazoki R, Bardai A, et al. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat. Genet. 2010;42:688-91.

19. Dekker LR, Bezzina CR, Henriques JP, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation. 2006;114:1140-5.

20. Yoshinaga M, Kucho Y, Sarantuya J, et al. Genetic characteristics of children and adults with long QT syndrome diagnosed by school-based electrocardiographic screening programs. Circ. Arrhythm. Electrophysiol. 2014;7:107-12.

21. Schwartz PJ, Stramba-Badiate M, Crotti L, et al. Prevalence of the congenital long QT syndrome. Circulation. 2009;120:1761-7.

22. Corrado D, Petticcia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005;26:516-24.

23. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascutar abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115(12):1643-455. doi:10.1161/CIRCULATIONAHA.107.181423.

24. Ljungqvist A, Jenoure P, Engebretsen L, et al. The International Olympic Committee (IOC) consensus statement on periodic health evaluation of elite athletes, March 2009. Br. J. Sports Meal. 2009;43:631-43.

25. Steinvil A, Chundadze T, Zeltser D, et al. Mandatory etectrocardiographic screening of athletes to reduce their risk for sudden death: proven fact or wishful thinking? J. Am. Coll. Cardiol. 2011;57:1291-6.

26. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ЕОК 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114:e385-e484.

27. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ЕОК Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2015;36(41):2793-867.

28. Piepoli MF, Hoes AW, Agewall S, et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81. doi:10.1093/eurheartj/ehw106.

29. Casella M, Carbucicchio C, Russo E, et al. Electrical storm in systemic sclerosis: Inside the electroanatomic substrate. World J Cardiol. 2014;6(10):1127-30. doi:10.4330/wjc.v6.i10.1127.

30. Dechering DG, Kochhauser S, Wasmer K, et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2013;10:158-64.

31. Cardinalti-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J. Cardiovasc Electrophysiol. 2007;18:1236-40.

32. Scheffold N, Herkommer B, Kandolf R, May AE. Lyme carditis diagnosis, treatment and prognosis. Dtsch Arztebl Int. 2015;112(12):202-8. doi:10.3238/arztebl.2015.0202.

33. Apshtein AE, Ideker RE. Ventricular Fibrillation in “Cardiac Electrophysiology. From Cell to Bedside”, ed. By Zipes DP and Jalife J, WB. Saunders Company. 2000. p. 677-84.

34. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for DeviceBased Therapy of Cardiac Rhythm Abnormalities. Circulation. 2008;117:e450-e408.

35. George S, Rodriguez I, Ipe D, et al. Computerized extraction of electrocardiograms from continuous 12-lead Holter recordings reduces measurement variability in a thorough QT study. J. Clin Pharmacol. 2012;52:1891-900.

36. Volosin K, Stadler RW, Wyszynski R, Kirchhof P. Tachycardia detection performance of implantable Loop recorders: results from a large ‘real-life' patient cohort and patients with induced ventricular arrhythmias. Europace. 2013;15:1215-22.

37. de Asmundis C, Conte G, Sieira J, et al. Comparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace. 2014;16:1231-5.

38. Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2011;8:256-62.

39. Nava A, Folino AF, Bauce B, et al. Signal-averaged electrocardiogram in patients with arrhythmogenic right ventricular cardiomyopathy and ventricular arrhythmias. Eur Heart J. 2000;21:58-65.

40. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography — summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J. Am CoU Cardiol. 2003;42:954-70.

41. Prastaro M, D'Amore C, Paolillo S, et al. Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Fail Rev. 2015;28:305-16.

42. Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation. J. Emerg Med. 2014;47:113-8.

43. Zellweger MJ, Hachamovitch R, Kang X, et al. Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J. Nud Cardiol. 2009;16:193-200.

44. Podrid PJ, Graboys TB. Exercise stress testing in the management of cardiac rhythm disorders. Med Clin North Am. 1984;68:1139-52.

45. Kang X, Berman DS, Lewin H, et al. Comparative ability of myocardial perfusion singlephoton emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J. 1999;137:949-57.

46. Zelias A, Stepinska J, Andres J, et al. Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography. Kardiol Pol. 2014;72:687-99.

47. Zaman S, Narayan A, Thiagalingam A, et al. Significance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction. Pacing Clin Electrophysiol. 2014;37:795-802.

48. Denes P, Uretz E, Ezri MD, Borbola J. Clinical predictors of electrophysiologic findings in patients with syncope of unknown origin. Arch Intern Med. 1988;148:1922-8.

49. Brignole M, Menozzi C, Moya A, et al. International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation. 2001;104:2045-50.

50. Brembilla-Perrot B, Suty-Selton C, Houriez P, et al. Value of non-invasive and invasive studies in patients with bundle branch block, syncope and history of myocardial infarction. Europace. 2001;3:187-94.

51. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8(8):1308-39.

52. Basso C, Burke M, Fornes P, et al. Association for European Cardiovascular P. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch. 2008;452:11-8.

53. Basso C, Carturan E, Pilichou K, et al. Sudden cardiac death with normal heart: molecular autopsy. Cardiovasc Pathol. 2010;19:321-5.

54. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsynegative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc. 2012;87:524-39.

55. Windecker S, Koth P, Alfonso F, et al. 2014 ЕОК/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ЕОК) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.

56. Roffi M, Patrono C, Cotter JP, et al. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.

57. Steg PG, James SK, Atar D, et al. ЕОК Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.

58. Hohnloser SH, Kuck KH, Dorian P, et al. Investigators D. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J. Med. 2004;351:2481-8.

59. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J. Med. 1997;336:1629-33.

60. Dumas F, Cariou A, Manzo-Sitberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200-7.

61. Noc M, Fajadet J, Lassen JF, et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. Eurointervention. 2014;10:31-7.

62. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the HeartRhythm Society. J. Am Coll Cardiol. 2018;72(14):1677-749.

63. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144:282-9.

64. Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J. Am Coil Cardiol. 2010;55:1713-20.

65. Nolan JP, Soar J, Zideman DA, et al. Group ERCGW. European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation. 2010;81:1219-76.

66. Soholm H, Wachte UK, Nietsen SL, et al. Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. Resuscitation. 2013;84:162-7.

67. Xiao G, Guo Q, Shu M, et al. Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis. Emerg. Med. J. 2013;30:91-100.

68. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-5.

69. Boersma E. Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur. Heart J. 2006;27:779-88.

70. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-etevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579-88.

71. Bowers TR, O'Neitt WW, Grines C, et al. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J. Med. 1998;338:933-40.

72. Gorenek B, Blomstrom-Lundqvist C, Brugada P, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EH RA, ACCA, and EAPCI task force. Europace. 2014;16:1655-73.

73. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trialRegistry). Am J Cardiol. 2008;102:1427-32.

74. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J. Med. 2001;345:1473-82.

75. Bougouin W, Marijon E, Puymirat E, et al. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J. 2014;35:116-22.

76. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J. Med. 2000;342:1937-45.

77. Buxton AE, Lee KL, Harley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J. Am Coil Cardiol. 2007;50:1150-7.

78. Gatzoutis KA, Tsiachris D, Arsenos P, et al. Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J. Cardiol. 2014;176:1449-51.

79. Exner DV, Kavanagh KM, Stawnych MP, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J. Am Coil Cardiol. 2007;50:2275-84.

80. Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (the European Myocardial Infarct Amiodarone Triat). J. Am Coil Cardiol. 2000;35:1263-75.

81. Auman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Am Coil Cardiol. 2002;39:1151-8.

82. Steinbeck G, Andresen D, Seidl K, et al. IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J. Med. 2009;361:1427-36.

83. Kelly P, Ruskin JN, VTahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and longterm survival. J .Am Coil Cardiol. 1990;15:267-73.

84. van der Burg AE, Bax JJ, Boersma E, et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation. 2003;108:1954-9.

85. Al Jaroudi WA, Refaat MM, Habib RH, et al. Genetic Risk Assessment of Defibrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol. 2015;115:924-31.

86. Pitt B, White H, Nicolau J, et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am Coil Cardiol. 2005;46:425-31.

87. Peck KY, Lim YZ, Horoffipper I, Krum H. Medical therapy versus implantable cardioverterdefibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J. Cardiol. 2014;173:197-203.

88. Chatterjee S, Udetl JA, Sardar P, et al. Comparable benefit of betablocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J. Cardiol. 2014;30:898-903.

89. Neumann F, Sousa-Uva M, Ahlsson A, et al. 2018 ЕОК/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165.

90. Dor V, Civaia F, Alexandrescu C, et al. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J. Thorac Cardiovasc Surg. 2011;141:905-16. doi:10.1016/j.jtcvs.2010.10.026.

91. Jones RH, Velazquez EJ, Michler RE, et al. STICH Hy-pothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. New England Journal of Medicine. 2009;360(17):1705-17.

92. Nguyen KT, Vittinghoff E, Dewland TA, et al. Ectopy on a Single 12-Lead ECG, Incident Cardiac Myopathy, and Death in the Community. J. Am Heart Assoc. 2017;6. pii: e006028. doi:10.1161/JAHA.117.006028.

93. Dukes JW, Dewland TA, Vittinghoff E, et al. Ectopy as a Predictor of Heart Failure and Death. J. Am Coll Cardiol. 2015;66:101-9. doi:10.1016/j.jacc.2015.04.062.

94. Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish “malignant” from “benign”? HeartRhythm. 2009;6:15071511.

95. Jamil HA, Mohammed SA, Gierula J, et al. Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. Am J. Cardiol. 2019;123:409-13. doi:10.1016/j.amjcard.2018.10.040.

96. Dabbagh GS, Bogun F. Predictors and therapy of cardiomyopathy caused by frequent ventricular ectopy. Curr Cardiol Rep. 2017;19:80.

97. Hyman MC, Mustin D, Supple G, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018;15:159-63.

98. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237-43.

99. Goy JJ, Tauxe F, Fromer M, et al. Ten-years follow-up of 20 patients with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1990;13:1142-7.

100. Mont L, Seixas T, Brugada P, et al. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. Am J. Cardiol. 1991;68:897-900.

101. Toivonen L, Nieminen M. Persistent ventricular tachycardia resulting in left ventricular dilatation treated with verapamil. Int J. Cardiol. 1986;13:361-5.

102. Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of tachycardia induced cardiomyopathy following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol. 1996;19:1391-2.

103. Prystowsky EN, Padanilam BJ, Joshi S, Fogel RI. Ventricular Arrhythmias in the Absence of Structural Heart Disease. J Am Coll Cardiol. 2012;59(20):1733-44. doi:10.1016/j.jacc.2012.01.036.

104. Lerman B. Ventricular tachycardia in patients with structurally normal hearts. D. P. Zipes, J. Jalife (Eds.). Cardiac Electrophysiology: From Cell to Bedside (5th ed.), WB Saunders, Philadelphia, PA, 2009, 657-667. Pacing Clin Electrophysiol. 1996;19:1391-2.

105. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Eng J. Med. 1977;297:750-7.

106. Engstrom G, Hedblad B, Janzon L, et al. Ventricular Arrhythmias during 24 hour ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. J. Intern Med. 1999;246:363-72.

107. Hoffmann A, Buhler FR, Burckhardt D. High-grade ventricular ectopic activity and 5 year survival in patients with chronic heart disease and in healthy subjects. Cardiology. 1983;70(S1):82-7.

108. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J. Am Coll Cardiol. 1993;22:1111-6.

109. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J. Am Coll Cardiol. 2005;45:697-704.

110. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.

111. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. в-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52. doi:10.1186/1471-2261-13-52.

112. Cleophas TJ, Zwinderman AH. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J. Clin Pharmacol Ther. 2001;39:383-8.

113. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J. Cardiol. 1997;80:35J-39J.

114. Fisher FD, Tyroler HA. Relationship between ventricular premature contractions on routine electrocardiography and subsequent sudden death from coronary heart disease. Circulation. 1973;47:712-9.

115. Al-Gobari M, Al-Aqeel S, Gueyffier F, Burnand B. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open. 2018;8:e021108. doi:10.1136/bmjopen-2017-021108.

116. Ahn J, Kim HJ, Choi JI, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PLoS One. 2017;12(10):e0185680. doi:10.1371/journal.pone.0185680.

117. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J. Med., 1991;324:781-8. doi:10.1056/NEJM199103213241201.

118. Cardiac Arrhythmia Suppression Trial (CAST) II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J. Med. 1992;327:227-33. doi:10.1056/NEJM199207233270403.

119. Ho AT, Pai SM, Timothy P, Pai RG. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2005;28:647-53.

120. Latchamsetty R, Bogun F. Premature Ventricular Complexes and Premature Ventricular Complex Induced Cardiomyopathy. Curr Probl Cardiol. 2015;40:379-422. doi:10.1016/j.cpcardiol.2015.03.002.

121. Baman TS, Lange DC, Ilg K, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865-59.

122. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469-75.

123. Koplan A, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J. Am Coll Cardiol. 2009;53:355-60.

124. Ruwald MH, Solomon SD, Foster E, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation. 2014;130:2278-86.

125. Julian D, Camm A, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667-74.

126. Cairns J, Connolly S, Roberts R, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet. 1997;349:675-82.

127. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J. Med. 2005;352:225-37.

128. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J. Am Coll Cardiol. 1997;30:791-8.

129. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.

130. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am. J. Cardiol. 1988;62:41A-45A.

131. Mahe I, Chassany O, Grenard AS, et al. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am. J. Cardiovasc. Drugs. 2003;3:33-41.

132. Masarone D, Limongelli G, Rubino M, et al. Management of Arrhythmias in Heart Failure. J Cardiovasc Dev Dis. 2017;4(1):3. doi: 10.3390/jcdd4010003.

133. Podrid P, Lown B. Selection of an antiarrhythmic drug to protect against ventricular fibrillation. In Proceedings of the first US-USSR Symposium on Sudden Death. DHEW publ. no. (NIH) 78-1470. 1978. pp 259-78.

134. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329:452-8.

135. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-71.

136. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J. Med. 1999;340:1855-62. doi:10.1056/NEJM199906173402402.

137. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30(10):1245-53. doi:10.1093/eurheartj/ehp100.

138. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.

139. Sroubek J, Buxton AE. Primary Prevention Implantable Cardiac Defibrillator Trials: What Have We Learned? Card Electrophysiol Clin. 2017;9(4):761-73. doi:10.1016/j.ccep.2017.08.006.

140. Aiba T, Kurita T, Taguchi A, et al. Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circ J. 2002;66:367-71.

141. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110:112-6.

142. Yager N, Wang K, Keshwani N, Torosoff M. Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances. BMJ Case Rep. 2015;2015:bcr2015209521. doi:10.1136/bcr-2015-209521.

143. Abdel Wahab A, Sapp J. Ventricular tachycardia with ICD shocks: when to medicate and when to ablate. Curr Cardiol Rep. 2017;19:105.

144. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J. Med. 2016;375:111-21. doi:10.1056/NEJMoa1513614.

145. Deyell MW, Steinberg C, Doucette S, et al. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol. 2018;29:603-8. doi:10.1111/jce.13431.

146. Gao D, Van Herendael H, Alshengeiti L, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J. Cardiovasc Pharmacol. 2013;62(2):199-204. doi:10.1097/FJC.0b013e31829651fe.

147. El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18:233-45.

148. Veenhuyzen GD, Wyse DG. Life threatening ventricular arrhythmias with transient or correctable causes. Minerva Cardioangiol. 2003;51:275-86.

149. Wyse DG, Friedman PL, Brodsky MA, et al. AVID Investigators. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38:1718-24.

150. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132 (suppl 2): S444-64.

151. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351:647-56.

152. Sasson C, Rogers MA, Dahl J, et al. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3:63-81.

153. Fogoros RN, Fiedler SB, Elson JJ. Efficacy of phenytoin in suppressing inducible ventricular tachyarrhythmias. Cardiovasc Drugs Ther. 1988;2(2):171-6. doi:10.1007/BF00051232.

154. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shockresistant ventricular fibrillation. N Engl J Med. 2002;346:884-90.

155. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;374(18):1711-22. doi:10.1056/NEJMoa1514204.

156. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-ofhospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871-8.

157. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33:199-205.

158. Kudenchuk PJ, Newell C, White L, et al. Prophylactic lidocaine for post resuscitation care of patients with out-ofhospital ventricular fibrillation cardiac arrest. Resuscitation. 2013;84:1512-8.

159. Callaham M, Madsen CD, Barton CW, et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA. 1992;268:2667-72.

160. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. 1998;339:1595-601.

161. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012;307:1161-8.

162. Long B, Koyfman AJ. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. Emerg Med. 2017;52(4):484-92. doi:10.1016/j.jemermed.2016.09.010.

163. Tang PT, Do DH, Li A, Boyle NG. Team Management of the Ventricular Tachycardia Patient. Arrhythmia & Electrophysiology Review. 2018;7(4):238-46. doi:10.15420/aer.2018.37.2.

164. Ohlow MA, Beierlein A, Muller S, et al. Stable tachycardia with wide QRS complex in prehospital emergency medicine. Dtsch Med Wochenschr. 2005;130(47):2694-8..

165. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999;281:1182-8.

166. Cobb LA, Weaver WD, Fahrenbruch CE, et al. Community-based interventions for sudden cardiac death. Impact, limitations, and changes. Circulation. 1992;85(suppl):I98-102.

167. Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002;288:3035-8.

168. Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA. 2003;289:1389-95.

169. Eckardt L, Breithardt G, Kirchhof P. Approach to wide complex tachycardias in patients without structural heart disease. Heart. 2006;92(5):704-11. doi:10.1136/hrt.2005.063792.

170. Hudson KB, Brady WJ, Chan TC, et al. Electrocardiographic manifestations: ventricular tachycardia. J Emerg Med. 2003;25(3):303-14.

171. Miller JM, Das MK, Yadav AV, et al. Value of the 12-lead ECG in wide QRS tachycardia. Cardiol Clin. 2006;24(3):439-51, ix-x.

172. Goldberger ZD, Rho RW, Page RL. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia. Am J Cardiol. 2008; 101(10):1456-66. doi:10.1016/j.amjcard.2008.01.024.

173. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78:43-6.

174. Markel DT, Gold LS, Allen J, et al. Procainamide and survival in ventricular fibrillation out-of-hospital cardiac arrest. Acad Emerg Med. 2010;17:617-23.

175. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38:1329-35.

176. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344:18-23.

177. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90:853-9.

178. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993;270:1589-95.

179. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102:742-7.

180. Belhassen B, Horowitz LN. Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol. 1984;54:1131-3.

181. Griffith MJ, Garratt CJ, Rowland E, et al. Effects of intravenous adenosine on verapamilsensitive “idiopathic” ventricular tachycardia. Am J Cardiol. 1994;73:759-64.

182. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000;36:811-23.

183. Belhassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981;46:679-82.

184. German LD, Packer DL, Bardy GH, et al. Ventricular tachycardia induced by atrial stimulation in patients without symptomatic cardiac disease. Am J Cardiol. 1983;52:1202-7.

185. Tsuchiya T, Okumura K, Honda T, et al. Effects of verapamil and lidocaine on two components of the re-entry circuit of verapamil-senstitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2001;37:1415-21.

186. Nogami A. Idiopathic left ventricular tachycardia: assessment and treatment. Card Electrophysiol Rev. 2002;6(4):448-57.

187. Diker E, Tezcan K, Ozdemir M, Goksel S. Adenosine sensitive left ventricular tachycardia. Pacing Clin Electrophysiol. 1998;21(1 Pt 1):134-6.

188. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology's NCDR. Am Heart J. 2011;161:864-70.

189. Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenous betablockers in patients with acute coronary syndrome — a meta-analysis of randomized triats. Int J Cardiol. 2013;168:915-21.

190. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-anatysis of randomized trials. Am J Med. 2014;127:939-53.

191. McMurray JJ, Adamopoutos S, Anker SD, et al. ЕОК Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ЕОК Eur Heart J. 2012;33:1787-847.

192. Wotfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricutar tachycardia associated with acute myocardial infarction. Circulation. 1991;84:1543-51.

193. Monsieurs KG, Nolan JP, Bossaert LL, et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 1. Executive summary. Resuscitation. 2015;95:1-80.

194. Piccini JP, Schulte PJ, Pieper KS, et al. Antiarrhythmic drug therapy for sustained ventricutar arrhythmias compticating acute myocardial infarction. Crit Care Med. 2011;39:78-83.

195. Zafari AM, Zarter SK, Heggen V, et al. A program encouraging early defibrillation results in improved inhospital resuscitation efficacy. J Am Coil Cardiol. 2004;44:846-52.

196. Umeda M, Morimoto A, Yokoyama K, et al. Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report. J Cardiol. 2007;50(4):263-9.

197. Josephson ME, Almendral J, Callans DJ. Resetting and entrainment of reentrant ventricular tachycardia associated with myocardial infarction. Heart Rhythm. 2014;11(7):1239-49.

198. Yoshida T, Naito Y, Nishimura K. Temporary ventricular overdrive pacing for electrical storm after coronary artery bypass grafting. Gen Thorac Cardiovasc Surg. 2011;59(11):756-9.

199. Chia PL, Loh SY, Foo D. Ventricular tachycardia storm: a case series and literature review. Med J Malaysia. 2012;67(6):582-4.

200. Reddy YM, Chinitz L, Mansour I, et al. Percutaneous left ventricular assist devices in ventricutar tachycardia ablation: mutticenter experience. Circ Arrhythm Electrophysiol. 2014;7:244-50.

201. Dor V, Sabatier M, Montiglio F, et al. Results of nonguided subtotal endocardiectomy associated with left ventricular reconstruction in patients with ischemic ventricular arrhythmias. Journal of Thoracic and Cardiovascular Surgery. 1994;107(5):1301-7.

202. Babokin V, Shipulin V, Batalov R, Popov S. Surgical ventricular reconstruction with endocardectomy along radiofrequency ablation-induced markings. Journal of Thoracic and Cardiovascular Surgery. 2013;146(5):1133-8.

203. Sartipy U, Albage A, Insulander P, Lindblom D. Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: the Karolinska approach. J. Interv. Card. Electrophysiol. 2007;19:171-8.

204. Ревишвили А. Ш. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва: Новое издательство, 2017. р. 702. ISBN: 978-5-9500922-0-6.

205. Bayes de Luna A, Coumel P, Leclerq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am. Heart J. 1989;117:151-9.

206. Josephson ME, Harken AH, Horowitz LN. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation. 1979;60:1430-9.

207. Krishnan SC, Josephson ME. Surgery for postinfarction ventricular tachycardia: is it obsolete? Pacing Clin. Electrophysiol. 2000;23:1295-301.

208. Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardias: feasibility and clinical outcome. Europace. 2014;16:1040-52.

209. Kovacs B, Reek S, Krasniqi N, et al. Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit? Cardiol Res Pract. 2018;2018:7373610. doi: 10.1155/2018/7373610.

210. Barraud J, Cautela J, Orabona M, et al. Wearable cardioverter defibrillator: Bridge or alternative to implantation? World J Cardiol. 2017;9(6):531-8. doi:10.4330/wjc.v9.i6.531.

211. Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infaretion. J Am Coil Cardiol. 2013;62:2000.

212. Liang JJ, Hodge DO, Mehta RA, et al. Outcomes in patients with sustained ventricutar tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate? Europace. 2014;16:1759-66.

213. Myerburg RJ, Wellens HJJ. Epidemiology of cardiac arrest. In Sudden Cardiac Death. Ed.: S. Priori, D. Zipes. Blackwell Publishing, 2005. 304 p.

214. Zipes DP. Epidemiology and mechanisms of sudden cardiac death. Can.J.Cardiol. 2005;21(Suppl. A):37A-40A.

215. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999;341(25):1882-90.

216. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. 1996;335:1933-40.

217. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Eng. J. Med. 2002;346: 877-83.

218. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 2004;350:2140-50.

219. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at risk for ventricular arrhythmias after coronary artery bypass graft surgery (Coronary Artery Bypass Graft (CABG) Patch Trial Investigators). New Eng J Med.1997;337:1569-75.

220. K0ber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality (DANISH). N Engl J Med. 2016;375:1221-30.

221. Bansch D, Antz M, Boczor S, et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy The Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-8.

222. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone Versus Implantable Cardioverter-Defibrillator: Randomized Trial in Patients With Nonischemic Dilated Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia — AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-12.

223. Kadish A, Dyer A, Daubert JP, et al. Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). N Engl J Med. 2004;350:2151-8.

224. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy A Meta-analysis of Randomized Controlled Trials. JAMA. 2004;292:2874-9.

225. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417-24.

226. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158-65.

227. Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation. 2001;104:1171-6.

228. Van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coil Cardiol. 2012;59:493-500.

229. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ЕОК Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ЕОК). Eur Heart J. 2014;35:2733-79.

230. O'Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of imptantabte cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116-25.

231. Daubert JC, Donal E, Linde C. A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy. Heart Fail. Rev. 2012;17(6):767-75.

232. Schinkel AF. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol. 2013;6:562-8.

233. Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006;113:1641-9.

234. Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of longterm follow-up and complications in 60 patients. Circulation. 2004;107:1503-8.

235. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000;101:2490-6.

236. Maskatia SA, Decker JA, Spinner JA, et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2012;33:141-9.

237. Rivenes SM, Keamey DL, Smith EO, et al. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation. 2000;102:876-82.

238. Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;382:1889-97.

239. Webber SA, Lipshultz SE, Sleeper LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation. 2012;126(10):1237-44.

240. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the Iong-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Imp[antable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation. 2010;2:1272-82.

241. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783-8

242. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-74.

243. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coil Cardiol. 2014;63:1300-8.

244. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation. 2003;108:965-70.

245. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-7.

246. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74.

247. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricutar tachycardia. Circulation. 2009;119:2426-34.

248. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;S:235-40.

249. Palladini G, Malamani G, Co F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Paring Ciin Electrophysiol. 2001;24:1228-33.

250. Dubrey SW, Bilazarian S, LaValley M, et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134:994-1001.

251. Reisinger J, Dubrey SW, LaValley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coil Cardiol. 1997;30:1046-51.

252. Te AL, Lin YJ, Chen YY, et al. Increased risk of ventricular tachycardia in patients with sarcoidosis during the very long term follow-up. Int J Cardiol. 2017;228:68-73. doi:10.1016/j.ijcard.2016.11.041.

253. Muratore CA, Batista SaLA, Chiate PA, et al. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America. Europace. 2009;11:164-8.

254. Martinelli L, de Siqueira SF, Sternick EB, et al. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in Chagas' heartdisease. Am J Cardiol. 2012;110:1040-5.

255. Barbosa MP, da Costa Rocha MO, de Oliveira AB, et al. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. Europace. 2013;15:957-62.

256. Gali WL, Sarabanda AV, Baggio JM, et al. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. Europace. 2014;16:674-80.

257. Bennett CE, Freudenberger R. The Current Approach to Diagnosis and Management of Left Ventricular Noncompaction Cardiomyopathy: Review of the Literature. Cardiol Res Pract. 2016;2016:5172308. doi:10.1155/2016/5172308.

258. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fatlot. Circulation. 2008;117:363-70.

259. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250-7.

260. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective imptantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coil Cardiol. 2008;51:1685-91.

261. Koyak Z, de Groot JR, Van Gelder IC, et al. Imptantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101-10.

262. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricutar isthmus. Circulation. 2007;116:2241-52.

263. Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012;110:109-17.

264. Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coil Cardiol. 2002;48:1675-80.

265. Gatzoulis HA, Bataji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975-81.

266. Cleland JGF, Daubert JC, Erdmann E, et al. The CARE-HF study (Cardiac Resynchronisation in Heart Failure study): rationale, design and end-points. Eur. J. Heart Fail. 2001;3(4):481-9.

267. Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 2010;363(25):2385-95.

268. Eickolt C, Siekiera M, Kirmanoglou K, et al. Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia. PloS ONE. 2012;7(11):1-7.

269. Young JB, Abraham WT, Smith AL, et al. Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure The MIRACLE ICD Trial. JAMA. 2003;289(20):2685-94.

270. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289(6):730-40.

271. Abraham WT. Cardiac resynchronization therapy. Prog. Cardiovasc. Dis. 2006;48(4):232-8.

272. McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann. Intern. Med. 2004;141(5):381-90.

273. Bogale N, Priori S, Cleland JG, et al. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur. J. Heart Fail. 2012;14(1):61-73.

274. Rivero-Ayerza M, Theuns DAMJ, Garcia-Garcia H, et al. Effects of cardiac resynchronization therapy on all cause mortality, mode of death and heart failure hospitalizations. A metaanalysis of randomized controlled trials. Eur Heart J. 2006;27(22):2682-8. doi:10.1093/eurheartj/ehl203.

275. Cleland JGF, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur. J. Heart Fail. 2005;7(6):1070-5.

276. Cleland JGF, Daubert JC, Erdmann E, et all. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure. Eur. Heart J. 2006;27(16):1928-32.

277. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol. 2009;54(20):1837-46.

278. Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592-9.

279. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.

280. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101:1800-6.

281. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36:1983-9.

282. Jacobsson J, Reitan C, Carlson J, et al. Atrial fibrillation incidence and impact of biventricular pacing on long-term outcome in patients with heart failure treated with cardiac resynchronization therapy. BMC Cardiovasc Disord. 2019;19(1):195. doi:10.1186/s12872-019-1169-1.

283. Healey JS, Hohnloser SH, Exner DV, et al.; RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012;5(5):566-70. doi:10.1161/CIRCHEARTFAILURE.112.968867.

284. Lopes C, Pereira T, Barra S. Cardiac resynchronization therapy in patients with atrial fibrillation: a meta-analysis. Rev Port Cardiol. 2014;33(11):717-25. doi:10.1016/j.repc.2014.05.008.

285. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1(6):500-7. doi:10.1016/j.jchf.2013.06.003.

286. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239-46.

287. Gasparini M, Auricchio A, Regoli F, et al. Four-Year Efficacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease Progression: The Importance of Performing Atrioventricular Junction Ablation in Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2006;48(4):734-43.

288. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:1780-7.

289. Tolosana JM, Hernandez Madrid A, Brugada J, et al.; SPARE Investigators. Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and ResynchronizationStudy). Am J Cardiol. 2008;102(4):444-9. doi:10.1016/j.amjcard.2008.04.008.

290. Ferreira AM, Adragao P, Cavaco DM, et al. Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace. 2008;10:809-15.

291. Ganesan AN, Brooks AG, Roberts-Thomson KC, et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol. 2012;59:719-26.

292. Orlov MV, Gardin JM, Slawsky M, et al. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J. 2010;159:264-70.

293. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16:1160-5.

294. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J. 2005;26:712-22.

295. Brignole M, Botto GL, Mont L, et al. Predictors of clinical efficacy of 'Ablate and Pace' therapy in patients with permanent atrial fibrillation. Heart. 2012;98:297-302.

296. Бокерия Л. А., Неминущий Н. М., Постол А. С. Сердечная ресинхронизирующая терапия. Формирование показаний и современные подходы к повышению эффективности метода. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(3):102-16. doi:10.17802/2306-1278-2018-7-3-102-116.

297. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: ameta-analysis. Europace. 2012;14(10):1490-7.

298. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-93.

299. Bogale N, Witte K, Priori S, et al. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail. 2011;13:974-83.

300. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol. 2007;30 Suppl 1:S23-30.

301. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace. 2006;8:51-5.

302. Van Geldorp IE, Vernooy K, Delhaas T, et al. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace. 2010;12:223-9.

303. Laurenzi F, Achilli A, Avella A, et al. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol. 2007;30:1096-104.

304. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103:1280-4.

305. Foley PW, Muhyaldeen SA, Chalil S, et al. Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace. 2009;11:495-501.

306. Frohlich G, Steffel J, Hurlimann D, et al. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. Eur Heart J. 2010;31:1477-85.

307. Paparella G, Sciarra L, Capulzini L, et al. Long-term effects of upgrading to biventricular pacing: differences with cardiac resynchronization therapy as primary indication. Pacing Clin Electrophysiol. 2010;33:841-9.

308. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail. 2014;16:1199-205.

309. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverterdefibrillator. N Engl J Med. 2010;363:36-44.

310. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944-53.

311. Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J. 2012;33:1351-9.

312. Dabiri Abkenari L, Theuns DA, Valk SD, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol. 2011;108:737-44.

313. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coil Cardiol. 2015;65:1605-15.

314. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657-65.

315. Auricchio A, Klein H, Geller CJ, et al. Clinical efficacy of the wearable cardioverterdefibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol. 1998;81:1253-6.

316. Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J. 2013;34:2230-42.

317. Kao AC, Krause SW, Handa R, et al., Wearable defibrillator use In heart Failure (WIF) Investigators. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123.

318. Adler A, Halkin A, Viskin S. Wearable cardioverter-defibrillators. Circulation. 2013;127:854-60.

319. Hallstrom AP, Omato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351:637-46.

320. Capucci A, Aschieri D, Piepoli MF, et al. Tripling survival from sudden cardiac arrest via early defibrillation without traditional education in cardiopulmonary resuscitation. Circulation. 2002;106:1065-70.

321. De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30:1500-5.

322. Tomzik J, Koltermann KC, Zabel M, et al. Quality of Life in Patients with an Implantable Cardioverter Defibrillator: A Systematic Review. Front Cardiovasc Med. 2015;2:34. doi:10.3389/fcvm.2015.00034.

323. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589-94.

324. Koopman HM, Vrijmoet-Wiersma CM, Langius JN, et al. Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter defibrillator. Pediatr Cardiol. 2012;33:569-75.

325. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace. 2010;12:1480-9.

326. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433-43.

327. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110;2591-6.

328. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation. 2005;111;2898-905.

329. Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;173:859-65.

330. Berg SK, Higgins M, Reilly CM, et al. Sleep quality and sleepiness in persons with implantable cardioverter defibrillators: outcome from a clinical randomized longitudinal trial. Pacing Clin Electrophysiol. 2012;35:431-43.

331. Vazquez LD, Kuhl EA, Shea JB, et al. Age-specific differences in women with implantable cardioverter defibrillators: an international multicenter study. Pacing Clin Electrophysiol. 2008;31:1528-34.

332. Morady F, Kadish AH, DiCarlo L, et al. Long term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990;82:2093-9.

333. Callans DJ, Menz V, Schwartzman D, et al. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol. 1997;29:1023-7.

334. Tada H, Hiratsuji T, Naito S, et al. Prevalence and characteristics of idiopathic outflow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outflow tract. Pacing Clin Electrophysiol. 2004;27:1240-9.

335. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coil Cardiol. 2008;52:139-47.

336. Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiological characteristics, catheter ablation, and identification from the 12-lead electrocardiogram. Circulation. 2006;113(13):1659-66. doi:10.1161/CIRCULATIONAHA.105.611640.

337. Tada H, Nogami A, Naito S, et al. Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outflow tract tachycardia. Jpn Circ J. 2001;65:723-30.

338. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic concepts relevant to ablation. Circ Arrhythm Electrophysiol. 2010;3:616-23.

339. Kumagai K, Yamauchi Y, Takahashi A, et al. Idiopathic left ventricular tachycardia originating from the mitral annulus. J Cardiovasc Electrophysiol. 2005;16:1029-36.

340. Yamada T, Litovsky SH, Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008;1:396-404.

341. Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular tachycardias arising from the aortic sinus of valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coil Cardiol. 2001;37:1408-14.

342. Ouyang F, Fotuhi P, Ha SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coil Cardiol. 2002;39:500-8.

343. Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and topography of the arrhythmia origin. Heart Rhythm. 2008;5:419-26.

344. Sekiguchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic and electrophysiologic characteristics of ventricular tachycardia originating within the pulmonary artery. J Am Coil Cardiol. 2005;45:887-95.

345. Timmermans C, Rodriguez LM, Crijns HJ, et al. Idiopathic left bundle-branch blockshaped ventricular tachycardia may originate above the pulmonary valve. Circulation. 2003;108:1960-7.

346. Sung RJ, Keung EC, Nguyen NX, Huycke EC. Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest. 1988;81:688-99.

347. Lerman BB, Belardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation. 1986;74:270-80.

348. Lerman BB. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation. 1993;87:382-90.

349. Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation. 1993;87:126-34.

350. Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J. 2000;139:1009-13.

351. Krittayaphong R, Saiviroonporn P, Boonyasirinant T, et al. Magnetic resonance imaging abnormalities in right ventricular outflow tract tachycardia and the prediction of radiofrequency ablation outcome. Pacing Clin Electrophysiol. 2006;29:837-45.

352. Khasnis A, Jongnarangsin K, Abela G, et al. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol. 2005;28:710-21.

353. O'Donnell D, Cox D, Bourke J, et al. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J. 2003;24:801-10.

354. Ito S, Tada H, Naito S, et al. Development and validation of an ECG algorithm for identifying the optimal ablation site for idiopathic ventricular outflow tract tachycardia. J Cardiovasc Electrophysiol. 2003;14:1280-6.

355. Koruth JS, Aryana A, Dukkipati SR, et al. Unusual complications of percutaneous epicardial access and epicardial mapping and ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol. 2011;4:882-8.

356. Roberts-Thomson KC, Steven D, Seller J, et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation. 2009;120:1465-73.

357. Makimoto H, Zhang Q, Tilz RR, et al. Aborted sudden cardiac death due to radiofrequency ablation within the coronary sinus and subsequent total occlusion of the circumflex artery. J Cardiovasc Electrophysiol. 2013;24:929-32.

358. Ho YS. Overview of cardiac anatomy relevant to catheter ablation. In: Wilber D., Packer D., Stevenson W., eds. Catheter Ablation of Cardiac Arrhythmias, 3rd edn. Cambridge, MA: Blackwell Scientific. 2008:3-17.

359. Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation. 1992;8S:1666-74.

360. Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm. 2005;2:934-9.

361. Crijns HJ, Smeets JL, Rodriguez LM, et al. Cure of interfascicular reentrant ventricular tachycardia by ablation of the anteriorfascicle of the left bundle branch. J Cardiovasc Electrophysiol. 1995;6:486-92.

362. Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1988;77:560-8.

363. Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the Purkinje network. Circulation. 2002;10S:462-9.

364. Ma FS, Ma J, Tang K, et al. Left posterior fascicular block: a new end point of ablation for verapamil-sensitive idiopathic ventricular tachycardia. Chin Med J (Engl). 2006;119:367-72.

365. Kottkamp H, Chen X, Hindricks G, et al. Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysiol. 1995;18:1285-97.

366. Nogami A, Naito S, Tada H, et al. Verapamil-sensitive left anterior fascicular ventricular tachycardia: results of radiofrequency ablation in six patients. J Cardiovasc Electrophysiol. 1998;9:1269-78.

367. Reithmann C, Hahnefeld A, Ulbrich M, et al. Different forms of ventricular tachycardia involving the left anterior fascicle in nonischemic cardiomyopathy: critical sites of the reentrant circuit in low-voltage areas. J Cardiovasc Electrophysiol. 2009;20:841-9.

368. Bogun F, EI-Atassi R, Daoud E, et al. Radiofrequency ablation of idiopathic left anterior fascicular tachycardia. J Cardiovasc Electrophysiol. 1995;6:1113-6.

369. Caceres J, Jazayeri P, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256-70.

370. Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation. 1988;78:246-57.

371. Mizusawa Y, Sakurada H, Nishizaki M, et al. Characteristics of bundle branch reentrant ventricular tachycardia with a right bundle branch block configuration: feasibility of atrial pacing. Europace. 2009;11:1208-13.

372. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624-50.

373. Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol. 2008;1:23-9.

374. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm. 2010;7:725-30.

375. Bogun F, Desjardins B, Crawford T, et al. Postinfarction ventricular arrhythmias originating in papillary musdes. J Am Coil Cardiol. 2008;S1:1794-802.

376. Yeh SJ, Wen MS, Wang CC, et al. Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coil Cardiol. 1997;38:1339-45.

377. Kondo K, Watanabe I, Kojima T, et al. Radiofrequency catheter ablation of ventricular tachycardia from the anterobasal left ventricle. Jpn Heart J. 2000;41:215-25.

378. Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coil Cardiol. 2005;4S:877-86.

379. Haissaguerre M, Derval N, Sachet F, et al. Sudden cardiac arrest associated with early repotarization. N Engl J Med. 2008;358:2016-23.

380. Haissaguerre M, Shah DC, Jais P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;3S9:677-8.

381. Bogun F, Good E, Reich S, et al. Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coil Cardiol. 2006;48:2500-7.

382. Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962-7.

383. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coil Cardiol. 2009;S4:522-8.

384. Nogami A, Sugiyasu A, Kubota S, Kato K. Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system. Heart Rhythm. 2005;2:646-9.

385. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and longterm outcomes in a prospective single-center study. Circulation. 2008;117:462-9.

386. Kojodjojo P, Tokuda M, Bohnen M, et al. Electrocardiographic left ventricular scar burden predicts clinical outcomes following infarct-related ventricular tachycardia ablation. Heart Rhythm. 2013;10:1119-24.

387. Della Bella P, Baratto F, Tsiachris D, et al. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation. 2013;127:1359-68.

388. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coil Cardiol. 2000;35:1905-14.

389. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773-82.

390. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21(1):47-53. doi:10.1111/j.1540-8167.2009.01563.x.

391. Visser CA, Kan G, David GK, et al. Two dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest. 1983;83:228-32.

392. Ezekowitz MD, Wilson DA, Smith EO, et al. Comparison of Indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med. 1982;306:1509-13.

393. Stratton JR, Lighty GWJr, Pearlman AS, Ritchie JL. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation. 1982;66:156-66.

394. Thanigaraj S, Schechtman KB, Perez JE. Improved echocardiographic delineation of left ventricular thrombus with the use of intravenous second-generation contrast image enhancement. J Am Soc Echocardiogr. 1999;12:1022-6.

395. Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol. 2008;52:148-57.

396. Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging. 2009;2:969-79.

397. Siontis KC, Kim HM, Sharaf Dabbagh G, et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm. 2017;14:1487-93.

398. Zghaib T, Ipek EG, Hansford R, et al. Standard ablation versus magnetic resonance imaging-guided ablation in the treatment of ventricular tachycardia. Circ Arrhythm Electrophysiol. 2018;11:e005973.

399. Andreu D, Penela D, Acosta J, et al. Cardiac magnetic resonance-aided scar dechanneling: influence on acute and long-term outcomes. Heart Rhythm. 2017;14:1121-8.

400. Dickfeld T, Tian J, Ahmad G, et al. MRI-guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverterdefibrillators. Circ Arrhythm Electrophysiol. 2011;4:172-84.

401. Fernandez-Armenta J, Berruezo A, Andreu D, et al. Three-dimensional architecture of scar and conducting channels based on high resolution ceCMR: insights for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol. 2013;6:528-37.

402. Gupta S, Desjardins B, Baman T, et al. Delayed-enhanced MR scar imaging and intraprocedural registration into an electroanatomical mapping system in post-infarction patients. JACC Cardiovasc Imaging. 2012;5:207-10.

403. Marra MP, Leoni L, Bauce B, et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol. 2012;5:91-100.

404. Nakahara S, Vaseghi M, Ramirez RJ, et al. Characterization of myocardial scars: electrophysiological imaging correlates in a porcine infarct model. Heart Rhythm. 2011;8:1060-7.

405. Ghannam M, Cochet H, Jais P, et al. Correlation between computer tomography- derived scar topography and critical ablation sites in postinfarction ventricular tachycardia. J Cardiovasc Electrophysiol. 2018;29:438-45.

406. Esposito A, Palmisano A, Antunes S, et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate: relationship between CT-segmented scar and electro-anatomic mapping. JACC Cardiovasc Imaging. 2016;9:822-32.

407. Yamashita S, Sacher F, Mahida S, et al. Image integration to guide catheter ablation in scar-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2016;27:699-708.

408. Komatsu Y, Cochet H, Jadidi A, et al. Regional myocardial wall thinning at multidetector computed tomography correlates to arrhythmogenic substrate in postinfarction ventricular tachycardia: assessment of structural and electrical substrate. Circ Arrhythm Electrophysiol. 2013;6:342-50.

409. Andreu D, Ortiz-Perez JT, Boussy T, et al. Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. Eur Heart J. 2014;35:1316-26.

410. Soto-Iglesias D, Acosta J, Penela D, et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm. 2018;15:814-21.

411. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657-65.

412. Kumar S, Baldinger SH, Romero J, et al. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2016;27:1437-47.

413. Acosta J, Penela D, Andreu D, et al. Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace. 2018;20:512-9.

414. Berte B, Relan J, Sacher F, et al. Impact of electrode type on mapping of scar-related VT. J Cardiovasc Electrophysiol. 2015;26:1213-23.

415. Yamashita S, Cochet H, Sacher F, et al. Impact of new technologies and approaches for post-myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circ Arrhythm Electrophysiol. 2016;9:e003901.

416. Hutchinson MD, Gerstenfeld EP, Desjardins B, et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythmia Electrophysiol. 2011;4:49-55.

417. Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2011;8:76-83.

418. Chopra N, Tokuda M, Ng J, et al. Relation of the unipolar low-voltage penumbra surrounding the endocardial low-voltage scar to ventricular tachycardia circuit sites and ablation outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25:602-8.

419. Soto-Becerra R, Bazan V, Bautista W, et al. Ventricular tachycardia in the setting of Chagasic cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10:e004950.

420. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2013;6:891-7.

421. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465-72.

422. Barnan TS, Lange DC, IIg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865-9.

423. Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013;5:735-41.

424. Schwartz PJ, Motolese M, Pollavini G. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992;3:2-16.

425. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term followup. Heart Rhythm. 2014;11:360-6.

426. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012;59:91-2.

427. Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684-90.

428. Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503-9.

429. Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197-201.

430. McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847-50.

431. Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defibrillators in a heart transplant population: A single-center experience. J Heart Lung Transplant. 2016;35:682-4.

432. Ruwald AC, Marcus F, Estes NA3rd, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur. Heart J. 2015;36:1735-43.

433. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084-91.

434. Marcus GM, Glidden DV, Polonsky B, et al. Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J. Am. Coll. Cardiol. 2009;S4:609-15.

435. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29-37.

436. Cronin EM, Bogun FM, Maury P, et al. ESC Scientific Document Group. 2019 HRS/ EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019;21(8):1143-4. doi:10.1093/europace/euz132. Erratum in: Europace. 2019;21(8):1144. Erratum in: J Arrhythm. 2020;36(1):214. Erratum in: Europace. 2020;22(3):505.

437. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2012;5(3):499-505.

438. Santangeli P, Zado ES, Supple GE, et al. Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(6):1413-21. doi:10.1161/CIRCEP.115.003562.

439. Berruezo A, Acosta J, Fernandez-Armenta J, et al. Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace. 2017;19:607-16.

440. Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ. Arrhythm. Electrophysiol. 2012;5:111-21.

441. Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ. Arrhythm. Electrophysiol. 2011;4:478-85.

442. Roguin A, Bomma CS, Nasir K, et al. Implantable cardioverterdefibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J. Am. Coil. Cardiol. 2004;43:1843-52.

443. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J. Am. Coil. Cardiol. 2011;58:1485-96.

444. Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985;71:63-71.

445. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the Iong-QT syndrome: gene-specific triggers for lifethreatening arrhythmias. Circulation. 2001;103:89-95.

446. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-4.

447. Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64:1167-74.

448. Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation nd torsades de pointes. J Am Coll Cardiol. 2016;67:1639-50.

449. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760-81.

450. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005;2(5):497-504.

451. Schwartz PJ, Priori SG Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QTsyndrome. Circulation. 2004;109:1826-33.

452. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCNSA and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381-6.

453. Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial Ann Noninvasive Electrocardiol. 2005;10:59-66.

454. Moss AJ, Zareba W, Schwarz KQ, Rosero S., McNitt S., Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 Iong-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289-93.

455. Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15:1389-406.

456. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587-95.

457. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43:1494-9.

458. Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J. 2005;5:25-34.

459. Marquez MF, Bonny A, Hemandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm. 2012;9:1995-2000.

460. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003;108:3092-6.

461. Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with Long-QT and Brugada syndromes. Circulation. 2003;108:925-8.

462. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123:1270-9.

463. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;71:1512-9.

464. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Meal. 2009;15:380-3.

465. Otde Nordkamp LR, Driessen AH, Odero A, et al. Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Neth Heart J. 2014;22:160-6.

466. Hofferberth SC, Cecchin F, Loberman D, Fynn-Thompson F. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricutar arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404-9.

467. Beaufort-Krot GC, Dijkstra SS, Bink-Boelkens MT. Natural history of ventricutar premature contractions in children with a structurally normal heart: does origin matter? Europace. 2008;10:998-1003.

468. Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coil Cardiol. 1999;33:2067-72.

469. Wang S, Zhu W, Hamilton RM, et al. Diagnosis specific characteristics of ventricutar tachycardia in children with structurally normat hearts. Heart Rhythm. 2010;7:1725-31.

470. Collins KK, Schaffer MS, Liberman L, et al. Fascicular and nonfascicular left ventricular tachycaralias in the young: an international multicenter study. J Cardiovasc Electrophysiol. 2013;24(6):640-8. doi:10.1111/jce.12105.

471. Schneider HE, Kriebel T, Jung K, et al. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm. 2010;7:731-9.

472. Школьникова М. А., Березницкая В. В. Желудочковые аритмии. Клинические рекомендации по детской кардиологии и ревматологии. Под ред. Школьниковой М. А., Алексеевой Е. И. М., 2011. Гл. 5. сс. 133-59.

473. Brugada J, Blom N, Sarquella-Brugada G, et al. European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-82. doi:10.1093/europace/eut082.

474. Lapage MJ, Bradley DJ, Dick M2nd. Verapamil in infants: an exaggerated fear? Pediatr Cardiol. 2013;34:1532-4.

475. Blaufox AD, Felix GL, Saul JP. Radiofrequency catheter ablation in infants

476. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004;109:1994-2000.

477. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944-54.

478. Crosson JE, Callans DJ, Bradley DJ, et al. PACES/HRS expert consensus statement on the evaluation and management of ventricular arrhythmias in the child with a structurally normal heart. Heart Rhythm. 2014;11(9):e55-78. doi: 10.1016/j.hrthm.2014.05.010.

479. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; разраб. А.Ш. Ревишвили. 3-е изд., доп. и перераб. М.: МАКС-Пресс, 2013. 595 с.

480. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34:2636-48.

481. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ. J. 2002;66:133-44.

482. Liberman L, Anderson B, Silver ES, et al. Incidence and characteristics of arrhythmias in pediatric patients with myocarditis: a multicenter study. J. Am. Coil. Cardiol. 2014;63:A483.

483. Kindermann I, Kindermann H, Kandolf R, et al. Predictors of outcome in patients with suspected myocardills. Circulation. 2008;118:639-48.

484. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-52. doi:10.1161/CIR.0b013e31829e8807.

485. Prochnau D, Surber R, Kuehnert H, et al. Successful use of a wearable cardioverterdefibrillator in myocarditis with normal ejection fraction. Clin. Res. Cardiol. 2010;99:129-31.

486. Chung HK. The role of the wearable cardioverter defibrillator in clinical practice. Cardiol. Clin. 2014;32:253-70.

487. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giantcell myocarditis in the era of combined immunosuppression. Grc. Heart Fail. 2013;6:15-22.

488. Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J. Cardiovasc. Magn. Reson. 2014;16:14.

489. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. Circ. J. 2011;75:734-43.

490. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J. Am. Coil. Cardiol. 2004;43:1137-44.

491. Plazzone P, Tsiachris D, della Bella P. Epicardial management of myocarditisrelated ventricular tachycardia. Eur. Heart J. 2013;34:244.

492. Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart. 2002;88:53-60.

493. Aranki SF, Santini F, Adams DH, et al. Aortic valve endocarditis. Determinants of early survival and late morbidity. Circulation. 1994;90:11175-82.

494. Yang F, Shah B, Iwai S, et al. ICD implantation and arrhythmia-free survival in patients with depressed LV function following surgery for valvular heart disease. Pacing Clin. Electrophysiol. 2008;31:1419-24.

495. Valles AG, Khawaja FJ, Gersh BJ, et al. Implantable cardioverter defibrillators in patients with valvular cardiomyopathy. J. Cardiovasc. Electrophysiol. 2012;2(3):1326-32.

496. Rosenheck S, Weiss A, Sharon Z. Therapy success and survival in patients with valvular heart disease and implantable cardioverter defibrillator. Int. J. Cardiol. 2010;144:103-4.

497. Johnson LL, Sciacca RR, Ellis K, et al. Reduced left ventricular myocardial blood flow per unit mass in aortic stenosis. Circulation. 1978;57:582-90.

498. Martinez-Rubio A, Schwammenthal Y, Schwammenthal E, et al. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term followup. Circulation. 1997;96:500-8.

499. Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation. 1997;96:4307-13.

500. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688-97.

501. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307:1292-301.

502. Laurent V, Petlieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150:54-8.

503. Meune C, Van Berto JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;54:209-10.

504. Pegitz-Zagrosek V, Btomstrom Lundqvist C, Borghi C, et al. ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology. Eur Heart J. 2011;32:3147-97.

505. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998;97:451-6.

506. Siu SC, Sermer M, Cotman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104:515-21.

507. Drenthen W, Pieper PG, Roos-Hessetink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol. 2007;47:2303-11.

508. Poos-Hessetink JW, Puys TP, Stein JI, et al. Outcome of pregnancy in patients with structural or ischemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. 2013;34:657-65.

509. Rodriguez-Manero M, Casado-Arroyo P, Sarkozy A, et al. The clinical significance of pregnancy in Brugada syndrome. Rev Esp Cardiol (Engl Ed). 2014;67:176-80.

510. Benito B, Berruezo A. Brugada syndrome and pregnancy: delving into the role of sex hormones in ion channelopathies. Rev Esp Cardiol (Engl Ed). 2014;67:165-7.

511. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006;97:1206-12.

512. Sharif-Kazemi MB, Ernkanjoo Z, Tavoosi A, et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol. 2011;34:el 8-e21.

513. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368:687-69.

514. Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118:583-91.

515. Gowda RM, Khan IA, Mehta NJ, et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol. 2003;88:129-33.

516. Habli M, O'Brien T, Nowack E, et al. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008;199:415.e1-415.eS.

517. Simantirakis EN, Schiza SI, Marketou ME, et al. Severe bradyarrhythmias in patients with sleepapnea: the effect of continuous positive airway pressure treatment: a longterm evaluation using an insertable loop recorder. Eur Heart J. 2004;25:1070-6.

518. Gami AS, Otson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coil Cardiol. 2013;62:610-6.

519. Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for allcause mortality: the Busselton Health Study. Sleep. 2008;31:1079-85.

520. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31:1071-8.

521. Guitleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol. 1983;S2:490-4.

522. Becker HF, Koehter U, Stammnitz A, Peter JH. Heart block in patients with sleep apnea. Thorax. 1998;S3(Suppl 3):S29-S32.

523. Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol. 1996;77:1310-4.

524. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173:910-6.

525. Hoffstein V, Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest. 1994;106:466-71.

526. Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med. 1977;63:348-58.

527. Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest. 2000;118:591-5.

528. Grimm W, Koehler U, Fus E, et al. Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway pressure therapy. Am J Cardiol. 2000;86:688-92.

529. Koehter U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnea: pathogenetic factors and effects of treatment. Eur Respir J. 1998;11:434-9.

530. Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and treatment may reduce the need for pacemaker therapy. Pacing Clin Electrophysiol. 1996;19:899-904.

531. Strotto PJJr, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370:139-49.

532. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785-91.

533. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-20.

534. Pelliccia A, Fagard R, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:1422-45.

535. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-41.

536. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596-601.

537. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 1989;13:1283-8.

538. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-12.

539. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21:883-9.

540. Клинические рекомендации “Желудочковые аритмии”ю Минздрава России, ФГБУ “ННПЦССХ им. А. Н. Бакулева” МЗ РФ Центр хирургической и интервенционной аритмологии. Москва, 2017. 38 с.

541. Yoshinaga M, Ushinohama H, Sato S, et al. Etectrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals. Circ Arrhythm Electrophysiol. 2013;6:932-8.

542. Narain R, Dhutia H, Merghani A, et al. Preventing sudden cardiac death in the young: results from a population-based screening program in the UK. European Journal of Preventive Cardiology. 2014;21, suppl. S1-6.

543. Kattman JR, Thompson PD, Lantos J, et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and brood institute working group. Circulation. 2011;123:1911-8.

544. Приказ Министерства здравоохранения Российской Федерации от 26.10.2017 № 869н “Об утверждении порядка проведения диспансеризации определенных групп взрослого населения”.

545. Приложение № 1 к приказу Министерства здравоохранения Российской Федерации от 10.08.2017 № 514н “О порядке прохождения несовершеннолетними медицинских осмотров, в том числе при поступлении в образовательные учреждения и в период обучения в них”.

546. Школьникова М. А., Харлап М.С., Ильдарова Р.А. Генетически детерминированные нарушения ритма сердца. Российский кардиологический журнал. 2011;(1):8-25.

547. Школьникова М. А. Первичные электрические заболевания сердца как причина внезапной смерти. Доктор.™. 2008;3:25-32.

548. Charron P, Arad M, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardiat Diseases. Eur. Heart J. 2010;31:2715-26.

549. Christiaans I, Birnie E, Bonsel GJ, et al. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. Eur. J. Hum Genet. 2008;16:1201-7.

550. Ormondroyd E, Oates S, Parker I, et al. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur. J. Hum. Genet. 2014;22:88-93.

551. Ingles J, Yeates L, Hunt L, et al. Health status of cardiac genetic disease patients and their at-risk retatives. Int. J. Cardiol. 2013;165:448-53.

552. Battista RN, Blancquaert I, Laberge AM, et al. Genetics in health care: an overview of current and emerging models. Public Health Genomics. 2012;15:34-45.

553. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet. Meal. 2008;10:117-20.

554. Christiaans I, van Langen IM, Birnie E, et al. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am. J. Med. Genet. A. 2009;149A:602-12.

555. McGorrian C, Constant O, Harper N, et al. Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome. Europace. 2013;15:1050-8.

556. Sherazi S, Zareba W, Daubert JP, et al. Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. Cardiol J. 2010;17(3):267-73.

557. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681-92.

558. Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763-9.

559. Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverterdefibrillators from implantation to end of life: an integrative review of patients' perspectives. Patient. 2014;7:243-60.

560. Stewart GC, Weintraub JR, Pratibhu PP, etal. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010;16:106-13.

561. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physician communication, and the implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571-7.

562. Ottenberg AL, Mueller PS, Topazian RJ, et al. ”It's not broke, so let's not try to fix it”: why patients decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol. 2014;37:1306-14.

563. Yuhas J, Mattocks K, Gravelin L, et al. Patients' attitudes and perceptions of implantable cardioverter-defibrillators: potential barriers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012;35:1179-87.

564. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89:68-75.

565. Adler A, Van der Werf C, Postema PG, et al. The phenomenon of “QT stunning”: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9:901-8.

566. Комолятова В. Н., Макаров Л. М., Киселева И. И. и др. Изменение интервала QT в ортостазе — новый диагностический маркер синдрома удлинённого интервала QT. Медицинский алфавит. 2019;2(22):18-21.

567. Schwartz PJ, Crotti L. QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation. 2011;124:2181-4.

568. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230-7.

569. Lee V, Hemingway H, Harb R, et al. The prognostic significance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review. Heart. 2012;98:1290-8.

570. Kovoor P, Love A, Hall J, et al. Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Internal Medicine Journal. 2005;35(9):518-25. doi:10.1111/j.1445-5994.2005.00896.x.

571. Pokorney SD, Miller AL, Chen AY, et al. Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA. 2015;313(24):2433. doi:10.1001/jama.2015.6409.

572. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. Journal of the American College of Cardiology. 2005;45(8):1259-65. doi:10.1016/j.jacc.2004.12.073.

573. Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous epicardial ablation of ventricular arrhythmias arising from the left ventricular summit: outcomes and electrocardiogram correlates of success. Circ Arrhythm Electrophysiol. 2015;8:337-43.

574. Rillig A, Meyerfeldt U, Birkemeyer R, et al. Catheter ablation within the sinus of Valsalva — A safe and effective approach for treatment of atrial and ventricular tachycardias. Heart Rhythm. 2008;5(9):1265-72. doi:10.1016/j.hrthm.2008.06.010.

575. Jankowska H, Dorniak K, Hellmann M, et al. Arguable ICD placement in a sarcoidosis patient with extensive cardiac involvement. Archives of Medical Science. 2020;16(3):707-8. doi:10.5114/aoms.2019.86708.

576. Cice G, Tagliamonte E, Ferrara L, Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J. 2000;21(15):1259-64. doi:10.1053/euhj.1999.1984.

577. McMurray J, K0ber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525-30. doi:10.1016/j.jacc.2004.09.076.

578. Ruwald AC, Gislason GH, Vinther M, et al. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study. EP Europace. 2018;20(FI2):f217-f224. doi:10.1093/europace/euy077.

579. Luria HM, Adelson EI, Miller AJ. Acute and Chronic Effects of an Adrenergic BetaReceptor Blocking Agent (Propranolol) in Treatment of Cardiac Arrhythmia. Circulation. 1966;34(5):767-73. doi:10.1161/01.CIR.34.5.767.

580. Mauritson DR, Winniford MD, Walker WS, et al. Oral Verapamil for Paroxysmal Supraventricular Tachycardia. Annals of Internal Medicine. 1982;96(4):409-12.

581. Gill JS, Ward DE, Camm AJ. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15(11 Pt 2):2122-6. doi:10.1111/j.1540-8159.1992.tb03033.x.

582. Yeh SJ, Kou HC, Lin FC, et al. Effects of oral diltiazem in paroxysmal supraventricular tachycardia. Am J Cardiol. 1983;52(3):271-8. doi:10.1016/0002-9149(83)90121-2.

583. Buckley MM, Grant SM, Goa KL, et al. Diltiazem. A Reappraisal of its Pharmacological Properties and Therapeutic Use. Drugs. 1990;39:757-806. doi:10.2165/00003495-199039050-00009.

584. Avanzas P, Arroyo-Espliguero R, Cosm-Sales J, et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004;175(1):151-7. doi:10.1016/j.atherosclerosis.2004.03.013.

585. Morici N, Cantoni S, Soriano F, et al. Alterazioni dell'emocromo nella sindrome coronarica acuta: ematologi e cardiologi a confronto. G Ital Cardiol (Rome). 2019;20(12):694-705. Italian. doi:10.1714/3271.32379.

586. Nunez J, Minana G, Bod^ V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633.

587. Suh S, Cho YR, Park MK, et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;13(2):e0193041. doi:10.1371/journal. pone.0193041.

588. Sibilitz KL, Benn M, Nordestgaard BG. Creatinine, eGFR and association with myocardial infarction, ischemic heart disease and early death in the general population. Atherosclerosis. 2014;237(1):67-75. doi:10.1016/j.atherosclerosis.2014.08.040.

589. Zhang QL, Brenner H, Koenig W, Rothenbacher D. Prognostic value of chronic kidney disease in patients with coronary heart disease: role of estimating equations. Atherosclerosis. 2010;211(1):342-7. doi:10.1016/j.atherosclerosis.2010.02.028.

590. Dobre D, Rossignol P, Metra M, Zannad F. Can we prevent or treat renal dysfunction in chronic heart failure? Heart Fail Rev. 2012;17(2):283-90. doi:10.1007/s10741-011-9264-0.

591. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000;86(9):897-902. doi:10.1016/s0002-9149(00)01118-8.

592. Kadowaki S, Okamura T, Hozawa A, et al., NIPPON DATA Research Group. Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia. 2008;51(4):575-82. doi:10.1007/s00125-007-0915-6.

593. Nishimura M, Nakayama K, Ishikawa Y. Cardiac arrhythmias caused by electrolyte imbalance. Nihon Rinsho. 1996;54(8):2207-12.

594. Pilarczyk K, Carstens H, Heckmann J, et al. The aspartate transaminase/alanine transaminase (DeRitis) ratio predicts mid-term mortality and renal and respiratory dysfunction after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2017;52(4):781-8. doi:10.1093/ejcts/ezx247.

595. Narita K, Ureshino H, Hashimoto S. Sustained ventricular tachycardia caused by subacute thyroiditis. Intern Med J. 2018;48(9):1160-2. doi:10.1111/imj.14018.

596. Tsai IH, Su YJ. Thyrotoxic periodic paralysis with ventricular tachycardia. J Electrocardiol. 2019;54:93-5. doi:10.1016/j.jelectrocard.2019.04.001.

597. Middeldorp ME, Elliott AD, Gallagher C, et al. Late-onset thyrotoxicosis after the cessation of amiodarone. Indian Pacing Electrophysiol J. 2020;20(6):265-268. doi:10.1016/j.ipej.2020.07.006.

Документы

Информация

Автор

Название журнала

Российский кардиологический журнал

Ключевые слова

Статья